<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013281</url>
  </required_header>
  <id_info>
    <org_study_id>TR2021SCH</org_study_id>
    <nct_id>NCT05013281</nct_id>
  </id_info>
  <brief_title>Suprachoroidal Hemorrhage Associated With Pars Plana Vitrectomy</brief_title>
  <official_title>Suprachoroidal Hemorrhage Associated With Pars Plana Vitrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze the characteristics, related risk factors, and prognosis of suprachoroidal&#xD;
      hemorrhage (SCH) associated with pars plana vitrectomy (PPV).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2010</start_date>
  <completion_date type="Actual">January 28, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pathogenesis</measure>
    <time_frame>baseline</time_frame>
    <description>pathogenesis of PPV-related SCH and incidence of PPV-related SCH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>vision acuity</measure>
    <time_frame>up to 7 weeks</time_frame>
    <description>the final vision acuity</description>
  </secondary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Suprachoroidal Hemorrhage (Diagnosis)</condition>
  <condition>Pars Plana Vitrectomy</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Suprachoroidal hemorrhage associated with pars plana vitrectomy</intervention_name>
    <description>SCH has a higher incidence rate after a second intraocular surgery in a vitrectomized eye which is associated with the lack of vitreous support and easier fluctuation of intraocular pressure. SCH associated with PPV is more localized and has a relatively good prognosis; high myopia and aphakic/ pseudophakic eyes are risk factors. Active treatment can effectively improve visual prognosis.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        any participants who treated with PPV and occured Suprachoroidal hemorrhage with PPV&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suprachoroidal hemorrhage associated with pars plana vitrectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with eye trauma-related Suprachoroidal hemorrhage were excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

